Advertisement Theraclone, Pfizer ink research pact - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Theraclone, Pfizer ink research pact

Theraclone Sciences have signed a multi-year research and development agreement with Pfizer.

The tie up will use Theraclone’s I-STAR technology for the discovery of protective monoclonal antibodies as a treatment for four undisclosed targets for infectious disease and cancer.

As per the terms of the agreement, both the companies will jointly work on discovery activity to identify reactive antibodies directed against up to two infectious disease targets and up to two cancer targets.

The agreement will allow Pfizer an exclusive license to therapeutic antibodies which will be discovered under this collaboration.

Under the contract, Pfizer is responsible to pay undisclosed royalties to Theraclone on sales of developed products.

Additionally, it will also pay up to $632m in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones.

Moreover, Pfizer will be responsible for preclinical and clinical development of the antibodies.

Theraclone interim CEO Steven Gillis said the I-STAR platform has been designed to discover reactive, potent antibodies with high specificity for valuable targets.

"This collaboration with Pfizer, and the recent published success of I-STAR to identify antibodies against novel targets in HIV and influenza, increase confidence in Theraclone’s approach to search the human immune repertoire to isolate rare and powerful human antibodies that may be of use in the treatment of multiple diseases," Gillis said.